BioSpace News Archive

ignify Health, a leading healthcare platform leveraging advanced analytics, technology and nationwide healthcare networks to create and power value-based programs, is offering a suite of Clinical Support Services and Caregiver Support Services to reduce clinical and social barriers to therapy initiation and adherence.

Labs performing the Centers for Disease Control’s (CDC) Flu SC2 Multiplex Assay, a single test to diagnose infection caused by SARS-CoV-2, influenza A, or influenza B, can now use two Promega instruments and a Promega nucleic acid purification kit in the protocol.

Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, announce the start of a collaboration with Valneva.

XtalPi Inc., an Artificial Intelligence (AI) drug discovery and development technology company, is presenting virtually at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 13, 2021 at 12:10 PM ET

MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation and research, has awarded over $1 million in funding to 11 researchers across the nation through its 2020 Extramural Research Grants Program.

- National Cancer Institute (NCI) study investigating zotiraciclib (ZTR) in combination with temozolomide (TMZ) demonstrates meaningful clinical efficacy - ZTR has a favorable safety profile and was found to be well tolerated - Based on positive top-line Phase 1b data, Adastra Pharmaceuticals, Inc. is steadfast in undertaking a registration-enabling clinical study in the first half of 2021

Actym Therapeutics Inc., a privately-held company focused on the development of immunotherapies to treat cancer from its attenuated, microbial-based STACT platform, announced today the appointments of Dr. Lawrence Fong and Dr. Michel Streuli.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the Pre-IND meeting requested on 22 December 2020 for HT-001 with the U.S. Food and Drug Administration (FDA) Division of Dermatology and Dental Products has been granted to receive written responses only from FDA that are targeted for delivery on F

Massive Bio, Inc. , a leader in precision medicine and artificial intelligence (AI)-enabled patient-centric oncology clinical trial enrollment, announced today it has launched its SYNERGY-AI Oncology Clinical Trial Command Center (OCTCC) with the mission to disrupt and accelerate the clinical trial enrollment process. Akin to the NASA Deep Space Network, SYNERGY-AI OCTCC is a real time data and communication network between pa

Establishment Labs Announces Participation in the 39 th Annual J.P. Morgan Healthcare Conference